

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 25, 2006

Signature: 

Farah Bushashia

Docket No.: VOS-021 (107070.130 US1)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregor CEVC et al. Confirmation No.: 9531
Application No.: 09/890,335 Art Unit: 1645
Filed: July 26, 2001 Examiner: B. J. Gangle
Title: NON-INVASIVE VACCINATION THROUGH THE SKIN

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:


This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: October 25, 2006



Ann-Louise Kerner, Ph.D.
Registration No.: 33,523
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000 (telephone)
(617) 526-5000 (facsimile)



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/890,335-Conf. #9531
				Filing Date	July 26, 2001
				First Named Inventor	Gregor CEVC
				Art Unit	1645
				Examiner Name	B. J. Gangle
Sheet	1	of	3	Attorney Docket Number	VOS-021 (107070.130 US1)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-4,383,993	05-17-1983	Hussain et al.	
	AB*	US-6,165,500	12-26-2000	Cevc et al.	
	AC*	US-20020048596-A1	04-25-2002	Cevc et al.	
	AD	US-09/890371	07-26-2001	Cevc et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	DE-4107152	09-10-1992	Cevc		
	BB	DE-4447287	11-07-1996	Cevc		
	BC	EP-0475160-B1	08-23-1991	Cevc		
	BD	WO-00/24377	05-04-2000	Cevc		
	BE	WO-90/09385	08-23-1990	Wiener		
	BF	WO-92/03122	03-05-1992	Cevc		
	BG	WO-98/17255	04-30-1998	Cevc		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	ALMEIDA et al., "Nasal Delivery of Vaccines", J. Drug Targeting, 3:455-467 (1996)	
	CB	BAGNASCO, et al., "Absorption and Distribution Kinetics of the Major Parietaria Judaica Allergen (Par j1) Administered By Noninjectable Routes in Healthy Human Beings", J. Allergy Clin. Immunol. 100:122-9 (1997)	
	CC	BIBGEROGLU, et al., "Treatment of Estrogen-Dependent Gynecological Disorders with the Gonadotropin Releasing Hormone Agonist Buserelin", Gynecol. Endocrinol. 5:109-22 (1991)	
	CD	BRUINS et al., "Effect of Acute and Chronic Treatment with Desglycinamide [Arg8] Vasopressin in Young Male and Female Volunteers", Peptides 16:179-86 (1995)	
	CE	DRAGHIA et al., "Gene Delivery into the Central Nervous System by Nasal Instillation in Rats", Gene-Ther. 2:418-23 (1995)	
	CF	DREJER et al., "Intranasal Administration of Insulin with Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects", Diab. Med. 9:335-340 (1992)	
	CG	FLANAGAN et al., "A Recombinant Human Adenovirus Expressing the Simian Immunodeficiency Virus Gag Antigen can Induce Long-Lived Immune Responses in Mice", J. Gen. Virol. 78:991-7 (1997)	
	CH	GIZURARSON et al., "Intranasal Administration of Insulin to Humans", Diabets Res. Clin. Pract. 12:71-84 (1991)	
Examiner Signature			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/890,335-Conf. #9531
				Filing Date	July 26, 2001
				First Named Inventor	Gregor CEVC
				Art Unit	1645
				Examiner Name	B. J. Gangle
Sheet	2	of	3	Attorney Docket Number	VOS-021 (107070.130 US1)

CI	GHIGO et al., "Short Term Administration of Intranasal or Oral Hexarelin, a synthetic Hexapeptide, Does Not Desensitize the Growth Hormone Responsiveness in Human Aging", Eur. J. Endocrinol. 135:407-102 (1996)	
CJ	HARRIS, A. S. "Review: Clinical Opportunities Provided by the Nasal Administration of Peptides", J. Drug Target. 1:101-16 (1993)	
CK	HUNEYCUTT et al., "Distribution of Vesicular Stomatitis Virus Proteins in the Brains of BALB/c Mice Following Intranasal Inoculation: An Immunohistochemical Analysis", Brain Res. 635:81-95 (1994)	
CL	HUSSAIN et al., "Does Increasing the Lipophilicity of Peptides Enhance Their Nasal Absorption?", J. Pharm. Sci. 80:1180-1 (1991)	
CM	ICHIKAWA et al., "Anti-Osteopenic Effect of Nasal Salmon Calcitonin in Type I Osteoporotic Rats: Comparison with Subcutaneous Dosing", Biol. Pharm. Bull. 17:911-13 (1994)	
CN	ILUM, L., "The Nasal Delivery of Peptides and Proteins", Trends. Biotechnol. 9:284-9 (1991)	
CO	ILUM et al., "Intranasal Insulin", Clinical Pharmacokinet. 23:30-41 (1992)	
CP	INVETTI et al., "Effect of Chronic Treatment with Octreotide Nasal Powder on Serum Levels of Growth Hormone, Insulin-like Growth Factor I, Insulin-like Growth Factor Binding Proteins 1 and 3 in Acromegalic Patients", J. Endocrinol. Invest. 19:548-55 (1996)	
CQ	KIDA et al., "CSF Drains Directly from the Subarachnoid Space into Nasal Lymphatics in the Rat. Anatomy, Histology and Immunological Significance", Neuropathol. Appl. Neurobiol. 19:480-448 (1993)	
CR	LAURSEN et al., "Bioavailability and Bioactivity of Three Different Doses of Nasal Growth Hormone (GH) Administered to GH-Deficient Patients: Comparison with Intravenous and Subcutaneous Administration", Eur. J. Endocrinol. 135:309-15 (1996)	
CS	MACHIDA et al., "Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) from Rat Nasal Mucosa", Pharm. Res. 10(9):1372-7 (1993)	
CT	MAEJIMA et al., "Comparison of the Effects of Various Fine Particles on IgE Antibody Production in Mice Inhaling Japanese Cedar Pollen Allergens", J. Toxicol. Environ. Health. 52:231-48 (1997)	
CU	MAITANI et al., "Influence of Molecular Weight and Charge on Nasal Absorption of Dextran and DEAE-dextran in Rabbits", Intl. J. Pharmaceut. 49:23-27 (1989)	
CV	MCMARTIN et al., "Analysis of Structural Requirements for the Absorption of Drugs and Macromolecules from the Nasal Cavity", J. Pharm. Sci. 76:535-540 (1987)	
CW	MORI et al., "Temperature- Sensitive Parainfluenza Type 1 Vaccine Virus Directly Accesses the Central Nervous System by Infecting Olfactory Neurons", J. Gen. Virol. 77:2121-4 (1996)	
CX	NAUMANN et al., "Vasopressin and Cognitive Processes: Two Event-Related Potential Studies", peptides 12:1379-84 (1991)	
CY	PASECHNIK et al., "Macromolecular Drug Delivery to the CNS with Protein Carriers", Exp. Opin. Invest. Drugs 5:1255-1276 (1996)	
CZ	PERRAS et al., "Sleep and Signs of Attention During 3 Months of Intranasal Vasopressin: A Pilot Study in Two Elderly Subjects", peptides 17:1253-55 (1996)	
CA1	PIETROWSKY et al., "Brain Potential Changes after Intranasal vs. Intravenous Administration of Vasopressin: Evidence for a Direct Nose-Brain Pathway for Peptide Effects in Humans", Biol. Psychiatry 39:332-40 (1996)	
CB1	PIHOKER et al., "Diagnostic Studies with Intravenous and Intranasal Growth Hormone-Releasing Peptide-2 in Children of Short Stature", J. Clin. Endocrinol. Metab. 80(10):2987-92 (1995)	
CC1	POHL et al., "Modulation of Pain Perception in Man by a Vasopressin Analogue", Peptides 17:641-7 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/890,335-Conf. #9531
				Filing Date	July 26, 2001
				First Named Inventor	Gregor CEVC
				Art Unit	1645
				Examiner Name	B. J. Gangle
Sheet	3	of	3	Attorney Docket Number	VOS-021 (107070.130 US1)

	CD1	SARKAR, M. "Drug Metabolism in the Nasal Mucosa", Pharm-Res. 9:1-9 (1992)	
	CE1	SHIMODA et al., "Effects of Dose, PH and Osmolarity on Intranasal Absorption of Recombinant Human Erythropoietin in Rats", Biol. Pharm. Bull. 18(5):734-9 (1995)	
	CF1	SPERBER et al., "Otologic Effects of Interferon Beta Serine in Experimental Rhinovirus Colds", Arch. Otolaryngol. Head. Neck. Surg. 118:933-6 (1992)	
	CG1	TING et al., "Microparticles of Polyvinyl Alcohol for Nsal Delivery. I. Generation by Spray-Drying and Spray-Desolvation", Pharm. Res. 9:1330-5 (1992)	
	CH1	TSUME, et al., "Quantitative Evaluation of the Gastrointestinal Absorption of Protein into the Blood and Lymph Circulation", Biol. Pharm. Bull. 19(10) 1332-1337 (1996)	
	CI1	WATANABE, et al., "Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) and Blood Leukocyte Dynamics Following Intranasal Administration in Rabbits", Biol. Pharm. Bull. 16:93-95 (1993)	
	CJ1	WATANABE et al., "Pharmacokinetics and Pharmacodynamics of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) following Intranasal Administration in Rabbits", J. Drug Target 3:231-38 (1995)	
	CK1	WSTENBERG et al., "Pharmacokinetics of DGAVP in Plasma Following Intranasal and Oral Administration to Healthy Subjects". Peptides 15:1101-4 (1994)	
	CL1	VAN DER WIEL, et al. "Intranasal Calcitonin Suppresses Increased Bone Resorption During Short-Term Immobilization: A Double-Blind Study of the Effects of Intranasal Calcitonin on Biochemical Parameters of Bone Turnover.", J. Bone Mineral Res. 8:1459-65 (1993)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--